These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 32615820)

  • 1. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
    Fujino T; Suda K; Mitsudomi T
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capmatinib for the treatment of non-small cell lung cancer.
    Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
    [No Abstract]   [Full Text] [Related]  

  • 4. The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.
    Rocco D; Gravara LD; Palazzolo G; Gridelli C
    Curr Med Chem; 2024; 31(21):3043-3056. PubMed ID: 37534484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
    Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
    Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
    J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
    Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
    J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
    Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
    Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
    Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.
    Zhen Q; Liu JF; Liu JB; Wang RF; Chu WW; Zhang YX; Tan GL; Zhao XJ; Lv BL
    Cancer Biol Ther; 2015; 16(4):549-57. PubMed ID: 25831463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL; Smit EF; Bauer TM
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting un-MET needs in advanced non-small cell lung cancer.
    Coleman N; Harbery A; Heuss S; Vivanco I; Popat S
    Lung Cancer; 2022 Feb; 164():56-68. PubMed ID: 35033939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].
    Han S; Ma X; Fang J
    Zhongguo Fei Ai Za Zhi; 2020 Jul; 23(7):609-614. PubMed ID: 32702795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Going After
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-MET inhibitors for advanced non-small cell lung cancer.
    Pasquini G; Giaccone G
    Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer].
    Pan S; Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):615-621. PubMed ID: 36002199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
    Dong Y; Xu J; Sun B; Wang J; Wang Z
    Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.